Gene therapy with phosphodiesterases 2A and 4B ameliorates heart failure and arrhythmias by improving subcellular cAMP compartmentation

Author:

Pavlaki Nikoleta12ORCID,Froese Alexander12,Li Wener3,De Jong Kirstie A12,Geertz Birgit24,Subramanian Hariharan12,Mohagaonkar Sanika12,Luo Xiaojing3,Schubert Mario3,Wiegmann Robert125,Margaria Jean Piero67,Ghigo Alessandra6ORCID,Kämmerer Susanne3,Hirsch Emilio6ORCID,El-Armouche Ali3,Guan Kaomei3ORCID,Nikolaev Viacheslav O12ORCID

Affiliation:

1. Institute of Experimental Cardiovascular Research, University Medical Center Hamburg-Eppendorf , Martinistr. 52, D-20246 Hamburg , Germany

2. DZHK (German Center for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck , Martinistr. 52, D-20246 Hamburg , Germany

3. Institute of Pharmacology and Toxicology, Technical University of Dresden , Dresden , Germany

4. Institute of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf , Martinistr. 52, D-20246 Hamburg , Germany

5. Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf , Hamburg , Germany

6. Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino , Torino , Italy

7. Cystic Kidney Disorders Unit, Division of Genetics and Cell Biology, Università Vita-Salute San Raffaele , Milan , Italy

Abstract

Abstract Aims Gene therapy with cardiac phosphodiesterases (PDEs), such as phosphodiesterase 4B (PDE4B), has recently been described to effectively prevent heart failure (HF) in mice. However, exact molecular mechanisms of its beneficial effects, apart from general lowering of cardiomyocyte cyclic adenosine monophosphate (cAMP) levels, have not been elucidated. Here, we studied whether gene therapy with two types of PDEs, namely PDE2A and PDE4B, can prevent pressure-overload-induced HF in mice by acting on and restoring altered cAMP compartmentation in distinct subcellular microdomains. Methods and results HF was induced by transverse aortic constriction followed by tail-vein injection of adeno-associated-virus type 9 vectors to overexpress PDE2A3, PDE4B3, or luciferase for 8 weeks. Heart morphology and function was assessed by echocardiography and histology which showed that PDE2A and especially PDE4B gene therapy could attenuate cardiac hypertrophy, fibrosis, and decline of contractile function. Live cell imaging using targeted cAMP biosensors showed that PDE overexpression restored altered cAMP compartmentation in microdomains associated with ryanodine receptor type 2 (RyR2) and caveolin-rich plasma membrane. This was accompanied by ameliorated caveolin-3 decline after PDE2A3 overexpression, reduced RyR2 phosphorylation in PDE4B3 overexpressing hearts, and antiarrhythmic effects of both PDEs measured under isoproterenol stimulation in single cells. Strong association of overexpressed PDE4B but not PDE2A with RyR2 microdomain could prevent calcium leak and arrhythmias in human-induced pluripotent stem-derived cardiomyocytes with the A2254V mutation in RyR2 causing catecholaminergic polymorphic ventricular tachycardia. Conclusion Our data indicate that gene therapy with phosphodiesterases can prevent HF including associated cardiac remodelling and arrhythmias by restoring altered cAMP compartmentation in functionally relevant subcellular microdomains.

Funder

ERA-CVD

European Union

German Aerospace Center

Publisher

Oxford University Press (OUP)

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3